Literature DB >> 30536532

AHNS series: Do you know your guidelines? Guideline recommendations for recurrent and persistent head and neck cancer after primary treatment.

Ryan McSpadden1, Chad Zender2, Antoine Eskander3.   

Abstract

Locoregional recurrent/persistent head and neck cancer following primary treatment is a significant challenge as it is usually difficult to treat and has worse outcomes compared to the primary setting. Surgical resection of a local or regional recurrence offers the best chance of cure when feasible. Local recurrence outcomes vary by subsite with laryngeal recurrences having the best prognoses and hypopharynx having the worst. Instances of persistent neck masses following primary nonsurgical treatment can be evaluated with positron emission tomography (PET) with CT (PET-CT) when there is no definitive diagnosis of a recurrence/persistence. Reirradiation with or without chemotherapy can be considered for primary treatment when surgery is not an option, for adjuvant treatment following salvage surgery, or for palliation. Immunotherapy represents a newer class of chemotherapeutic agents. Current guidelines recommend enrollment in clinical trials especially when surgery is not an option as outcomes remain universally poor in the recurrent/persistent setting.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; education; guidelines; head and neck surgery; persistent cancer; recurrent cancer

Mesh:

Substances:

Year:  2018        PMID: 30536532     DOI: 10.1002/hed.25443

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Clinical practice guidelines for the management of recurrent head and neck cancer: a systematic review and quality appraisal.

Authors:  Emma De Ravin; Joseph Lu; Mandy Salmon; Sanjena Venkatesh; Dominic Romeo; Alvaro Moreira; Karthik Rajasekaran
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-12       Impact factor: 3.236

2.  Salvage surgery for patients with residual/persistent diseases after improper or insufficient treatment of oral squamous cell carcinoma: can we rectify these mistakes?

Authors:  Yue He; Zhonglong Liu; Surui Sheng; Weijin Gao; Xiao Tang; Xiaoguang Li; Chunyue Ma
Journal:  BMC Cancer       Date:  2021-07-31       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.